Improved prediction of early-onset coronary artery disease using APOE ε4, BChE-K, PPARγ2 Pro12 and ENOS T-786C in a polygenic model

Clinical Biochemistry

Volumn 39, Issue 2, 2006, Pages 109-114

  Nassar, Bassam A ^a,b   Rockwood, Kenneth ^a   Kirkland, Susan A ^a   Ransom, Thomas P ^a   Darvesh, Sultan ^a   MacPherson, Kathleen ^a   Johnstone, David E ^a   O'Neill, Blair J ^a   Bata, Iqbal R ^a   Andreou, Pantelis ^a   Jeffery, Julie S ^a   Cox, Jafna L ^a   Title, Lawrence M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

AGE OF ONSET; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BUTYRYLCHOLINESTERASE; CORONARY ARTERIOSCLEROSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MODELS, GENETIC; MUTATION; NITRIC OXIDE SYNTHASE TYPE III; PPAR GAMMA;

EID: 32844460963     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2005.10.002     Document Type: Article

References (50)

1. S.E. Humphries, P.M. Ridker, and P.J. Talmud Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation Arterioscler. Thromb. Vasc. Biol. 24 2004 628 636
2. Q. Yang, M.J. Khoury, and L. Botto Improving prediction of complex diseases by testing for multiple disease-susceptibility genes Am. J. Hum. Genet. 72 2003 636 649
3. B.A. Nassar, J. Dunn, and L.M. Title Relation of genetic polymorphisms of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B-100 and glycoprotein IIIa and early onset coronary heart disease Clin. Biochem. 4 1999 275 282
4. B.A. Nassar, S. Darvesh, and L.D. Bevin Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease Clin. Biochem. 35 2002 205 209
5. L. Frederiksen, K. Brodbaek, and M. Fenger Studies of the Pro12Ala polymorphism of the PPAR-γ gene in the Danish Monica Cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome J. Clin. Endocrinol. Metab. 87 2002 3989 3992
6. T. Pischon, J.K. Pai, and J.E. Manson Peroxisome proliferation-activated receptor-γ2 P12A polymorphism and risk of coronary heart disease in US men and women Arterioscler. Thromb. Vasc. Biol. 25 2005 1654 1658
7. S.S. Deeb, L. Fajas, and M. Nemoto A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nat. Genet. 20 1998 284 287
8. J. Ek, S.A. Urhammer, and T.I. Sorensen Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men Diabetologia 42 1999 892 895
9. M. Gurnell PPARγ and metabolism: insights from the study of human genetic variants Clin. Endocrinol. 59 2003 267 277
10. -786→C mutation in the 5′-flanking region of the endothelial nitric oxide gene is associated with coronary spasm Circulation 99 1999 2864 2870
11. M.E. Hyndeman, H.G. Parsons, and S. Verma T-786→C mutation in endothelial nitric oxide synthase is associated with hypertension Hypertension 39 2002 919 922
12. G. Ghilardi, M.L. Biondi, and M. DeMonti Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene Clin. Chem. 48 2002 989 993
13. -786C and Glu298Asp polymorphisms of the endothelial nitric oxide synthase gene affect the forearm blood flow responses of Caucasian hypertensive patients is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study J. Am. Coll. Cardiol. 41 2003 938 945
14. M.G. Colombo, U. Paradossi, and M.G. Andreassi Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease Clin. Chem. 49 2003 389 395
15. -786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study J. Am. Coll. Cardiol. 41 2003 930 937
16. -786→C mutation in the 5′-flanking region of the endothelial nitric oxide gene is associated with myocardial infarction, especially without coronary organic stenosis Am. J. Cardiol. 86 2000 628 634
17. N. Jeerooburkhan, L.C. Jones, and S. Bujac Genetic and environmental determinants of plasma nitrogen oxide and risk of ischemic heart disease Hypertension 38 2001 1054 1061
18. J.W. Stephens, and S.E. Humphries The molecular genetics of cardiovascular disease: clinical implications J. Intern. Med. 253 2003 120 127
19. P. Armitage M.A. Berry Statistical Methods in Medical Research 2nd ed. 1987 Blackwell Scientific Publications London
20. G. Gandelman, and M.M. Bodenheimer Screening coronary arteriography in the primary prevention of coronary artery disease Heart Dis. 5 2003 335 344
21. F. Cambien, O. Poirier, and V. Nicaud Sequence diversity in 36 candidate genes for cardiovascular disorders Am. J. Hum. Genet. 65 1999 183 191
22. E.J. Topol, J. McCarthy, and S. Gabriel Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction Circulation 104 2001 2641 2644
23. Y. Yamada, H. Izawa, and S. Ichihara Prediction of the risk of myocardial infarction from polymorphism in candidate genes N. Engl. J. Med. 347 2002 1916 1923
24. D. Altshuler, J.N. Hirschhorn, and M. Klannemark The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Nat. Genet. 26 2000 76 80
25. J. Davignon, R.E. Gregg, and C.F. Sing Apolipoprotein E polymorphism and atherosclerosis Arteriosclerosis 8 1988 1 21
26. P.W. Wilson, R.H. Myers, and M.G. Larsen Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring study JAMA 272 1994 1666 1671
27. F.M. van Bockxmeer, and C.D.S. Mamotte Apolipoprotein e4 homozygosity in young men with coronary heart disease Lancet 340 1992 879 880
28. M.N. Payne, E. Green, and M.R. Walker Apolipoprotein e4 and coronary artery disease Lancet 340 1992 1350
29. P.W.F. Wilson Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease Clin. Chem. 41 1995 165 169
30. C.A. Abbott, M.I. Mackness, and S. Kumar Relationship between serum butyrylcholinesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus Clin. Sci. 85 1993 77 81
31. V.M. Alcantara, and E.A. Chatuad-Freire-Maia Butyrylcholinesterase activity and risk factors for coronary artery disease Scand. J. Clin. Lab. Invest. 62 2002 399 404
32. E. Kyger, R. Wiegand, and L. Lange Cloning of the bovine pancreatic cholesterol esterase/lysophospholipase Biochem. Biophys. Res. Commun. 164 1989 1302 1309
33. J. Kálmán, A. Juhász, and Z. Janka Serum butyrylcholinesterase activity in hyperlipidemia Atherosclerosis 173 2004 145 146
34. C. De Vriese, F. Gregoire, and R. Lema-Kisoka Ghrelin degradation by serum and tissue homogenates: identification of cleavage sites Endocrinology 145 2004 4997 5005
35. S. Darvesh, D.A. Hopkins, and C. Geula Neurobiology of butyrylcholinesterase Nat. Rev., Neurosci. 4 2003 131 138
36. D.J. Lehmann, C. Johnston, and A.D. Smith Synergy between the genes for butyrylcholi-nesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease Hum. Mol. Genet. 6 1997 1933 1936
37. N. Marx, G. Sukhova, and C. Murphy Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro Am. J. Pathol. 153 1998 17 23
38. M.R. Mehrabi, P. Haslmayer, and S. Humpeler Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARγ) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy Eur. J. Heart Fail. 5 2003 733 739
39. M. Ricote, A.C. Li, T.M. Wilson, and C.J. Kelly The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation Nature 391 1998 79 82
40. L. Nagy, P. Tontonoz, and J.G.A. Alvarez Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell 93 1998 229 240
41. P. Tontonoz, L. Nagy, J.G.A. Alvarez, and V.A. Thjomazy PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 1998 241 252
42. A.R. Tall, P. Costet, and N. Wang Regulation and mechanisms of macrophage cholesterol efflux J. Clin. Invest. 110 2002 899 904
43. A. Chawla, Y. Barak, and L. Nagy PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat. Med. 7 2001 48 52
44. G. Chinetti, S. Lestavel, and V. Bocher PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophages foam cells through stimulation of the ABCA1 pathway Nat. Med. 7 2001 53 58
45. K.J. Moore, E.D. Rosen, and M.L. Fitzgerald The role of PPAR-γ in macrophage differentiation and cholesterol uptake Nat. Med. 7 2001 41 47
46. C. Jiang, A.T. Ting, and B. Seed PPAR-γ agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
47. 12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds J. Clin. Endocrinol. Metab. 86 2001 536 541
48. A. Enbergs, R. Bürger, and H. Reinecke Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy Eur. Heart J. 21 2000 45 52
49. G.A. Diamond, and J.S. Forrester Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease N. Engl. J. Med. 300 1979 1350 1358
50. R.S. Blumenthal, D.M. Becker, and L.R. Yanek Detecting occult coronary disease in a high-risk asymptomatic population Circulation 107 2003 702 707